trastuzumab,tucatinib
seagen
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib']
tucatinib plus trastuzumab for previously treated metastatic btc with her2 positive. median pfs of 5.5 months. #asco23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists